Improvement in the regulation of the vitamin K antagonist acenocoumarol after a standard initial dose regimen: Prospective validation of a prescription model

Journal of Thrombosis and Thrombolysis

Volumn 27, Issue 2, 2009, Pages 207-214

  Van Geest Daalderop, Johanna H H ^a   Hutten, Barbara A ^b   Péquériaux, Nathalie C V ^a   Levi, Marcel ^b   Sturk, Augueste ^b  

^a JEROEN BOSCH HOSPITAL   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Acenocoumarol; Dose model; Eventual dose; Initial dose regimen

Indexed keywords

ACENOCOUMAROL; ALLOPURINOL; ANTIVITAMIN K; AZATHIOPRINE; CARBAMAZEPINE; COLCHICINE; COLESTYRAMINE; DISULFIRAM; LEVOTHYROXINE; LOW MOLECULAR WEIGHT HEPARIN; METHOTREXATE; PHENYTOIN; PREDNISONE; THIAMAZOLE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE CALCULATION; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE REGIMEN; DRUG INDICATION; EVENING DOSAGE; FEMALE; HEALTH CARE QUALITY; HEART ATRIUM FIBRILLATION; HUMAN; INDIVIDUALIZATION; INTERNATIONAL NORMALIZED RATIO; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL MODEL; PRESCRIPTION; PRIORITY JOURNAL; STANDARDIZATION; TREATMENT DURATION; VALIDATION PROCESS; VENOUS THROMBOEMBOLISM;

ACENOCOUMAROL; ADULT; AGE DISTRIBUTION; AGE FACTORS; AGED; AGED, 80 AND OVER; ALGORITHMS; DRUG DOSAGE CALCULATIONS; DRUG MONITORING; HUMANS; INTERNATIONAL NORMALIZED RATIO; MIDDLE AGED; PRESCRIPTIONS; PROSPECTIVE STUDIES; VITAMIN K;

EID: 62149088930     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11239-008-0203-4     Document Type: Article

References (23)

1. Ansell J, Hirsh J, Poller L et al (2004) The pharmacology and management of the vitamin K antagonists: The seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 126:204S-223S
2. Van Geest-Daalderop JHH, Sturk A, Levi M et al (2004) Extent and quality of anticoagulation treatment with coumarin derivatives by the Dutch thrombosis services. Ned Tijdschr Geneesk 148:730-735. Dutch
3. Gadisseur APA, van der Meer FJM, Adriaansen HJ et al (2002) Therapeutic quality control of oral anticoagulant therapy comparing the short-acting acenocoumarol and the long-acting phenprocoumon. Br J Haematol 117:940-946
4. Rosendaal FR, Cannegieter SC, van der Meer FJM, Briët E (1993) A method to determine the optimal intensity of oral anticoagulation therapy. Thromb Haemost 39:236-239
5. Van Geest-Daalderop JHH, Hutten BA, Sturk A, Levi M (2003) Age and first INR after initiation of oral anticoagulant therapy with acenocoumarol predict the maintenance dosage. J Thromb Thrombolysis 15:197-203
6. Büller HR, Agnelli G, Hull RD et al (2004) Antithrombotic therapy for venous thromboembolic disease: The seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 126:401S-428S
7. Koopman MMW, Prandoni P, Piovella F et al, The Tasman Study Group (1996) Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. N Engl J Med 334:682-687
8. Weiss P, Soff GA, Halkin H, Seligsohn U (1987) Decline of proteins C and S and factors II, VII, IX and X during the initiation of warfarin therapy. Thromb Res 45:783-790
9. Hutten BA, Prins MH, Redekop WK et al (1999) Comparison of three methods to assess therapeutic quality control of treatment with vitamin K antagonists. Thromb Haemost 82:1260-1263
10. Crowther MA (2003) Oral anticoagulant initiation: Rationale for the use of warfarin dosing nomograms. Semin Vasc Med 3:255-260
11. Hylek EM, Go AS, Chang Y et al (2003) Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med 349:1019-1026
12. Kearon C, Ginsberg JS, Kovacs MJ, et al, Extended low-intensity anticoagulation for thromboembolism investigators (2003) Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med 349:631-639
13. Rombouts EK, Rosendaal FR, van der Meer FJM (2007) Daily vitamin K supplementation improves anticoagulant stability. J Thromb Haemost 5:2043-2048
14. Sconce E, Avery P, Wynne H, Kamali F (2007) Vitamin K supplementation can improve stability of anticoagulation for patients with unexplained variability in response to warfarin. Blood 109:2419-2423
15. Van Geest-Daalderop JHH, Hutten BA, Péquériaux NCV et al (2007) The influence on INRs and coagulation factors of the time span between blood sample collection and intake of phenprocoumon or acenocoumarol: Consequences for the assessment of the dose. Thromb Haemost 98:738-746
16. Marco F, Gutiérrez JI, Orkolaga K et al (2006) Patients who take uneven doses of acenocoumarol exhibit significant fluctuating levels of anticoagulation. Blood Coagul Fibrinolysis 17:509-512
17. Bodin L, Verstuyft C, Tregouet DA et al (2005) Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity. Blood 106:135-140
18. Schalekamp T, Brassé BP, Roijers JFM et al (2006) VKORC1 and CYP2C9 genotypes and acenocoumarol anticoagulation status: Interaction between both genotypes affects overanticoagulation. Clin Pharmacol Ther 80:13-22
19. Oldenburg J, Bevans CG, Fregin A, Geisen C, Müller-Reible C, Watzka M (2007) Current pharmacogenetic developments in oral anticoagulation therapy: The influence of variant VKORC1 and CYP2C9 alleles. Thromb Haemost 98:570-578
20. Sconce EA, Kahn TI, Wynne HA, Avery P, Monkhouse L, King BP, Wood P, Kesteven P, Daly AK, Kamali F (2005) The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: Proposal for a new dosing regimen. Blood 106:2329-2333
21. Carlquist JF, Horne BD, Muhlestein JB, Lappé DL, Whiting BM, Kolek MJ, Clarke JL, James BC, Anderson JL (2006) Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: A prospective study. J Thromb Thrombolysis 22:191-197
22. Veeger NJGM, Piersma-Wichers M, Tijssen JGP et al (2005) Individual time within target range in patients treated with vitamin K antagonists: Main determinant of quality of anticoagulation and predictor of clinical outcome. A retrospective study of 2300 consecutive patients with venous thromboembolism. Br J Haematol 128:513-519
23. Kovacs MJ, Rodger M, Anderson DR et al (2003) Comparison of 10-mg and 5-mg warfarin initiation nomograms together with low-molecular-weight heparin for outpatient treatment of acute venous thromboembolism. A randomized, double-blind, controlled trial. Ann Intern Med 138:714-719